TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (https://covid19.who.int/, 11 September 2020). In a life-threatening situation, where there is no specific and licensed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Mohammad Azam, Jamal, Qazi Mohammad Sajid, Rehman, Suriya, Almatroudi, Ahmad, Alzohairy, Mohammad A., Alomary, Mohammad N., Tripathi, Takshashila, Alharbi, Ali H., Adil, Syed Farooq, Khan, Mujeeb, Shaheer Malik, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. on behalf of King Saud University. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527303/
https://www.ncbi.nlm.nih.gov/pubmed/34909057
http://dx.doi.org/10.1016/j.arabjc.2020.09.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527303/
https://www.ncbi.nlm.nih.gov/pubmed/34909057
http://dx.doi.org/10.1016/j.arabjc.2020.09.037

Ejemplares similares